

Table 3. Drugs in Phase 2 (Completed and Recruiting) and Phase 3 Clinical Development for HS

Drug	Structure	Target	ClinicalTrials.gov Identifier	Status
Phase 3				
Secukinumab	Monoclonal antibody	IL-17A	NCT03713632 NCT03713619	Active, not recruiting
Phase 2				
INCB054707	Small molecule	Janus kinase 1	NCT03607487	Completed
Bimekizumab	Monoclonal antibody	IL-17A and IL-17F	NCT03248531	Completed
Apremilast	Small molecule	Phosphodiesterase 4	NCT03049267 NCT02695212	Completed
Risankizumab	Monoclonal antibody	IL-23 p19	NCT03926169	Active, not recruiting
Iscalimab (CFZ533)	Monoclonal antibody	CD40	NCT03827798	Recruiting
Avacopan (C5aR antagonist)	Small molecule	C5a receptor	NCT03852472	Active, not recruiting
Bermekimab	Monoclonal antibody	IL-1 α	NCT03512275	Completed